Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 037 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 037 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride replaces potassium ions lost from the body; dextrose provides caloric supplementation and prevents ketosis; sodium chloride maintains electrolyte balance and hydration.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion of 0.037% potassium chloride in 10% dextrose and 0.9% sodium chloride. The typical adult dose is 500-1000 mL as a continuous infusion at a rate of 1-2 mL/min (equivalent to 0.37-0.74 mg/min potassium chloride), adjusted based on serum potassium levels, with maximum infusion rate of 10 mEq/h potassium and daily maximum of 200 mEq potassium. Frequency: continuous infusion as needed.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium: terminal half-life ~2-3 hours in plasma, but whole-body turnover is slower; clinical context: dosing intervals depend on renal function and serum K+ monitoring. Dextrose: rapidly cleared, half-life <15 minutes. Sodium: not applicable as steady-state regulated by renal function.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium: renal excretion (90-95%), with minor fecal (<5%) and negligible biliary elimination. Dextrose: primarily metabolized to CO2 and water. Sodium: renal excretion (95-100%) with minor fecal loss.
Category C
Category A/B
Electrolyte
Electrolyte